🔴 Lipocine is trading 10.5% down in after-hours trading

Lipocine is trading at $1.97, down 10.45% after hours, with no confirmed late-breaking catalyst in available reporting.

• It closed at $2.20 on October 7, 2026.
• Earlier that day, Lipocine announced Health Canada approval of TLANDO through partner Verity Pharmaceuticals, which plans a Canadian launch by year-end.
• The positive approval news does not explain the after-hours decline; major U.S. indexes were down less than 0.5%.